Non-small-cell lung cancer
Non-small-cell lung cancer
复制标题
DOI：
10.1016/s0140-6736(10)62101-0
复制
发表时间：
2011-11-12
期刊：
影响因子：
168.9
通讯作者：
Shepherd, Frances A.
中科院分区：
文献类型：
--
作者：
Goldstraw, Peter;Ball, David;Shepherd, Frances A.
自上次Lancet肺癌研讨会以来的十年中，在非小细胞肺癌（NSCLC）的分类，诊断和治疗的许多方面都取得了进展。一个国际专家小组聚集在一起，重点关注非小细胞肺癌的流行病学和病理分类的变化，CT筛查和其他技术的作用，可以更早地诊断和更有效地治疗这种疾病，以及最近推出的第七版TNM分类及其与其他预后因素的关系，如生物标志物。我们还描述了治疗方面的进展，已经看到了新一代化疗药物的引入，特定阶段组完全切除后辅助化疗的优势，计划和管理放射治疗的新技术，以及评估和降低手术治疗风险的新手术方法。
In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pathological classification of NSCLC, the role of CT screening and other techniques that could allow earlier diagnosis and more effective treatment of the disease, and the recently introduced seventh edition of the TNM classification and its relation to other prognostic factors such as biological markers. We also describe advances in treatment that have seen the introduction of a new generation of chemotherapy agents, a proven advantage to adjuvant chemotherapy after complete resection for specific stage groups, new techniques for the planning and administration of radiotherapy, and new surgical approaches to assess and reduce the risks of surgical treatment.